DocGo Inc.

NASDAQ:DCGO

Medical - Care Facilities

Healthcare
$0.71 -4.29%

-$0.02 today

Market cap
$70.14M
Beta
1.00
P/E (TTM)
-0.3
EPS (TTM)
-$1.90
52W Low $0.49High $1.78

Volume 1.64M

Average 0.87M

DCGO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

DocGo Inc.NASDAQ: DCGO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of $3.22M fell 33.2% year over year, behind the +9.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 2.8% from the prior quarter. Over 3 fiscal years it compounded at +29.4% a year.

Context

  • Stock-based compensation amounted to 5.4% of revenue in FY2025, up 3.2 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -33.2% toward the trailing-twelve-month pace of +9.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.22M+2.8% QoQ
Last fiscal yearDec 2025
$17.44M+27.9% YoY
LTMMar 2026
$15.84M+9.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.2%——
1 year+27.9%——
3-year CAGR+29.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
17.44M USD
Year-over-year change
+27.9%
4-year CAGR
+88.7%

Stock-Based Compensation vs competitors

How DCGO compares with its peers on the latest reported figures

  • DCGO's LTM Mar 2026 stock-based compensation of $15.84M is the largest of the 9 companies compared; the peer median is $3.91M.
  • Its year-over-year change of +9.4% is the 2nd highest of 9, against a peer median of -19.1%.
  • Stock-based compensation amounts to 5.2% of revenue for DCGO, versus a peer median of 47.1%.
DCGO Competitors Peer median
Stock-Based Compensation for DCGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DCGODocGo Inc.LTM Mar 2026$15.84M +9.4%+29.4%5.2%
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M -55.6%-11.3%8.0%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$10.08M -60.8%-22.0%60.3%
RCELAVITA Medical, Inc.LTM Mar 2026$7.93M -41.7%+10.8%11.0%
COYACoya Therapeutics, Inc.LTM Mar 2026$5.41M +63.4%+174.5%68.1%
OVIDOvid Therapeutics Inc.LTM Mar 2026$2.41M -6.9%-9.8%33.9%
IMMXImmix Biopharma, Inc.LTM Mar 2026$2.15M -27.0%+57.6%—
VANIVivani Medical, Inc.LTM Mar 2026$1.45M -10.0%+4.6%—
MBOTMicrobot Medical Inc.LTM Mar 2026$1.02M -11.2%-15.5%974.3%
Peer median (excluding DCGO) $3.91M-19.1%-2.6%47.1%

Competitors are the stored peer set for DCGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income19.18M30.74M6.86M19.99M(196.37M)
Depreciation & Amortization7.07M10.57M16.43M15.88M15.66M
Deferred Income Tax(630.38K)(9.96M)(1.98M)3.47M7.75M
Stock-Based Compensation1.38M8.05M20.97M13.63M17.44M
Change in Working Capital(28.8M)(13.18M)(113.12M)19.52M81.66M
Accounts Receivables(58M)(8.42M)(160.52M)41.27M112.5M
Inventory00000
Accounts Payables11.88M3.64M(1.78M)8.56M(17.64M)
Other Working Capital17.31M(8.4M)49.18M(30.32M)(13.19M)
Other Non-Cash Items(142.67K)2.64M6.62M(2.16M)108.31M
Operating Cash Flow(1.95M)28.87M(64.22M)70.34M34.45M
Capital Expenditures(6.66M)(5.5M)(10.13M)(5.84M)(7.43M)
Acquisitions (Net)(1.96M)(32.95M)(19.46M)(310.45K)(16.4M)
Purchases of Investments(655.88K)00(5M)0
Sales of Investments655.88K00013.16M
Other Investing Activities(1.82M)(2.3M)(2.84M)(1.73M)(31.3M)
Investing Cash Flow(8.59M)(38.45M)(29.88M)(10.87M)(39.08M)
Debt Repayment(2.82M)(3.94M)20.7M613.55K(35.17M)
Common Stock Issued178.1M01.58M00
Common Stock Repurchased(479.33K)(3.73M)0(13.76M)(10.83M)
Dividends Paid000(1.29T)0
Other Financing Activities(19.6M)1.49M(21.17M)1.29T(4.82M)
Financing Cash Flow155.21M(6.18M)1.12M(24.15M)(50.82M)
Effect of Forex Changes(21.41K)761.23K1.09M(190.64K)595.8K
Net Change in Cash144.65M(15M)(91.89M)35.12M(54.85M)
Free Cash Flow(8.6M)23.37M(74.35M)64.5M27.02M

DocGo Inc.

NASDAQ:DCGO

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.